Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pagoclone

Known as: 1H-Isoindol-1-One, 2-(7-Chloro-1,8-Naphthyridin-2-yl)-2,3-Dihydro-3-(5-Methyl-2-Oxohexyl)-, (+)-, 2-(7-chloro-1.8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IsoindolesNaphthyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Multicomponent Synthesis of Isoindolinones by RhIII Relay Catalysis: Synthesis of Pagoclone and Pazinaclone from Benzaldehyde.
A practical one-pot isoindolinone synthesis enabled by RhIII catalysis was developed. The advantage of this protocol is that it… Expand
2010
2010
Exploratory Randomized Clinical Study of Pagoclone in Persistent Developmental Stuttering: The EXamining Pagoclone for peRsistent dEvelopmental Stuttering Study
Introduction: Stuttering is a speech disorder in which the flow of speech is disrupted by repetitions, prolongation, and blocks… Expand
2010
2010
Comments on article by Maguire et al: pagoclone trial: questionable findings for stuttering treatment.
  • R. Ingham
  • Journal of clinical psychopharmacology
  • 2010
    • Corpus ID: 43371705
 
2008
2008
[(18)F]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils.
In this study a novel series of isoindol-1-one and isoindol-1,3-dione derivatives for beta-amyloid-specific binding agents is… Expand
2008
2008
Preliminary effects of pagoclone, a partial GABAA agonist, on neuropsychological performance
Pagoclone is a novel cyclopyrrolone that acts as a partial GABAA receptor agonist. Preclinical studies suggest that pagoclone may… Expand
  • table 1
  • table 2
2006
2006
The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone
The cyclopyrrolone pagoclone binds with roughly equivalent high affinity (0.7-9.1nM) to the benzodiazepine binding site of human… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2006
2006
Evaluation of the Abuse Potential of Pagoclone, a Partial GABAA Agonist
Abstract: This study assessed the abuse potential of pagoclone, a partial agonist at the &ggr;-aminobutyric acid type A (GABAA… Expand
2005
2005
A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist
The GABA-ergic system is central to many anxiety disorders and has therefore received much attention. Benzodiazepines are highly… Expand
  • figure 1
Review
2003
Review
2003
Pagoclone Indevus.
  • Alan Bateson
  • Current opinion in investigational drugs
  • 2003
    • Corpus ID: 34466303
Pagoclone is a cyclopyrrolone GABAA receptor modulator under development by Indevus for the potential treatment of panic and… Expand
2001
2001
Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder
Pagoclone is a cyclopyrrolone that is believed to act as a partial agonist at the γ-aminobutyric acid (GABA) A/benzodiazepine… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE